Usefulness of event-related potentials in the assessment of mild cognitive impairment

Papaliagkas, Vasileios; Kimiskidis, Vasilios Κ.; Tsolaki, Magda; Anogianakis, G.

doi:10.1186/1471-2202-9-107

Cited by 106 publications

(74 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An important degree of freedom is the EEG recording condition: one may record EEG: (i) while the subject is at rest (with open or closed eyes); (ii) while the subject performs working-memory or other tasks; (iii) while the subject is being stimulated with auditory, visual, tactile, or other signals (see, e.g., [11][12][13][14][15]). Depending on the recording situation, EEG signals may be more or less discriminative for MCI and AD; a systematic exploration of different recordings conditions with the aim of diagnosing MCI and AD needs to be conducted.…”

Section: Resultsmentioning

confidence: 99%

On the Early Diagnosis of Alzheimer’s Disease from EEG Signals: A Mini-Review

Dauwels

Vialatte

Cichocki

2010

Advances in Cognitive Neurodynamics (II)

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

On the Early Diagnosis of Alzheimer’s Disease from EEG Signals: A Mini-Review

Dauwels

Vialatte

Cichocki

2010

Advances in Cognitive Neurodynamics (II)

View full text Add to dashboard Cite

show abstract

“…Currently, most functional EEG biomarkers [302] are based on spatio-temporal features such as the peak amplitude or latency of event-related potentials (ERPs) [303] (e.g. the N400/P600 ERPs which are cognitive indicators of episodic memory encoding [304]).…”

Section: Functional Neuroelectrical/neuromagnetic Markersmentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

102

View full text Add to dashboard Cite

Recent advances in understanding the molecular mechanisms underlying various paths toward the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that "treatments" need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD

show abstract

“…ERPs, along with other EEG measures, have proven to be a useful marker in neurodegenerative conditions. [2][3][4][5] ERP components of recognition memory are sensitive to decline in old age 6 and amnestic mild cognitive impairment (aMCI). 7 Studies have proposed ERPs as a sensitive method for early detection of AD, separating EEG activity related to AD pathology from normal aging.…”

mentioning

confidence: 99%

Event-related potential markers of brain changes in preclinical familial Alzheimer disease

Quiroz

Ally²,

Celone³

et al. 2011

Neurology

View full text Add to dashboard Cite

Objectives: Event-related potentials (ERPs) can reflect differences in brain electrophysiology underlying cognitive functions in brain disorders such as dementia and mild cognitive impairment. To identify individuals at risk for Alzheimer disease (AD) we used high-density ERPs to examine brain physiology in young presymptomatic individuals (average age 34.2 years) who carry the E280A mutation in the presenilin-1 (PSEN1) gene and will go on to develop AD around the age of 45.Methods: Twenty-one subjects from a Colombian population with familial AD participated: 10 presymptomatic subjects positive for the PSEN1 mutation (carriers) and 11 siblings without the mutation (controls). Subjects performed a visual recognition memory test while 128-channel ERPs were recorded.Results: Despite identical behavioral performance, PSEN1 mutation carriers showed less positivity in frontal regions and more positivity in occipital regions, compared to controls. These differences were more pronounced during the 200-300 msec period. Discriminant analysis at this time interval showed promising sensitivity (72.7%) and specificity (81.8%) of the ERP measures to predict the presence of AD pathology. Conclusions:Presymptomatic PSEN1 mutation carriers show changes in brain physiology that can be detected by high-density ERPs. The relative differences observed showing greater frontal positivity in controls and greater occipital positivity in carriers indicates that control subjects may use frontally mediated processes to distinguish between studied and unstudied visual items, whereas carriers appear to rely more upon perceptual details of the items to distinguish between them. These findings also demonstrate the potential usefulness of ERP brain correlates as preclinical markers of AD. Neurology Recognition memory impairments in Alzheimer disease (AD) have been linked to neocortical association areas including temporal and parietal lobes.1 Event-related potentials (ERPs) are less expensive, more widely available, and more comfortable than many other imaging modalities (e.g., MRI, PET, SPECT). ERPs, along with other EEG measures, have proven to be a useful marker in neurodegenerative conditions. 2-5 ERP components of recognition memory are sensitive to decline in old age 6 and amnestic mild cognitive impairment (aMCI). 7 Studies have proposed ERPs as a sensitive method for early detection of AD, separating EEG activity related to AD pathology from normal aging. [8][9][10][11][12] Preclinical markers and early detection are increasingly

show abstract

Usefulness of event-related potentials in the assessment of mild cognitive impairment

Abstract: Background: The aim of this study was to determine if changes in latencies and amplitudes of the major waves of Auditory Event-Related Potentials (AERP), correlate with memory status of patients with mild cognitive impairment (MCI) and conversion to Alzheimer's disease (AD).

Cited by 106 publications

References 32 publications

On the Early Diagnosis of Alzheimer’s Disease from EEG Signals: A Mini-Review

On the Early Diagnosis of Alzheimer’s Disease from EEG Signals: A Mini-Review

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Event-related potential markers of brain changes in preclinical familial Alzheimer disease

Contact Info

Product

Resources

About